A German study released this week has found that the A.30 variant of the Coronavirus effectively evades the protection afforded by the Pfizer and AstraZeneca ‘vaccines’.
The A.30 variant was first identified by scientists as originating in Tanzania, and further cases were subsequently found in Sweden and Angola around autumn (NZ time).
The study published in the peer-reviewed journal Cellular & Molecular Immunology, concluded that the A.30 variant showed improved ability to enter most host cells, including kidney, liver, and lung cells.
The summary stated:
[the] A.30 exhibits a cell line preference not observed for other viral variants and efficiently evades neutralization by antibodies elicited by ChAdOx1 nCoV-19 [AstraZeneca] or BNT162b2 [Pfizer] vaccination.”
